|
WO2021081052A1
|
|
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
WO2021076797A1
|
|
Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase beta
|
|
WO2021072268A1
|
|
A viral exposure signature for detection of early stage hepatocellular carcinoma
|
|
WO2021055787A1
|
|
Methods of isolating t cell populations
|
|
WO2021050900A1
|
|
Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
|
|
WO2021050962A1
|
|
Cancer detection and classification
|
|
WO2021026290A1
|
|
T cells having enhanced anti-tumor activity
|
|
WO2021025984A1
|
|
Radiolabeled sugars for imaging of fungal infections
|
|
WO2021003297A1
|
|
Monoclonal antibodies that bind egfrviii and their use
|
|
WO2020264353A1
|
|
Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alpha
|
|
WO2020264269A1
|
|
T cell receptors recognizing r175h or y220c mutation in p53
|
|
WO2020257408A1
|
|
Interleukin-27 producing b-cells and uses thereof
|
|
US2020369649A1
|
|
Autophagy modulators for use in treating cancer
|
|
WO2020227228A2
|
|
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2020236411A1
|
|
A scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase
|
|
WO2020219886A1
|
|
High-resolution cerebrospinal fluid-suppressed t2*-weighted magnetic resonance imaging of cortical lesions
|
|
WO2020210785A1
|
|
D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
|
|
WO2020210603A1
|
|
Hybrid nucleic acid switches
|
|
US2020348299A1
|
|
Methods for detection of flavivirus antibodies
|
|
WO2020190771A1
|
|
Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
|
